Compare · NVO vs QNTM
NVO vs QNTM
Side-by-side comparison of Novo Nordisk A/S (NVO) and Quantum Biopharma Ltd. (QNTM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and QNTM operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $195.92B, about 6055.9x QNTM ($32.4M).
- Over the past year, NVO is down 36.6% and QNTM is down 29.6% - QNTM leads by 7.0 points.
- NVO has been more active in the news (6 items in the past 4 weeks vs 3 for QNTM).
- NVO has more recent analyst coverage (25 ratings vs 0 for QNTM).
- Company
- Novo Nordisk A/S
- Quantum Biopharma Ltd.
- Price
- $43.88+3.99%
- $5.50-3.84%
- Market cap
- $195.92B
- $32.4M
- 1M return
- +20.30%
- +23.99%
- 1Y return
- -36.63%
- -29.60%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 6
- 3
- Recent ratings
- 25
- 0
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest QNTM
- Quantum BioPharma Provides Corporate Update
- SEC Form 6-K filed by Quantum Biopharma Ltd.
- Quantum BioPharma Licensee Unbuzzd Wellness Inc. Appoints Richard Buzbuzian as CEO to Lead Nationwide Commercialization of Innovative, Clinically Validated Hangover Remedy and Alcohol Metabolism Accelerant
- SEC Form 6-K filed by Quantum Biopharma Ltd.
- Quantum BioPharma Wins Significant Court Challenge in USD $700,000,000 Claim as Defendants Joint Motion to Dismiss Lawsuit Alleging Market Manipulation by CIBC World Markets and RBC Dominion Securities is Denied
- SEC Form 6-K filed by Quantum Biopharma Ltd.
- SEC Form 6-K filed by Quantum Biopharma Ltd.
- Quantum Biopharma Provides Corporate Update
- SEC Form 6-K filed by Quantum Biopharma Ltd.
- Quantum Biopharma's 2025 Audited Year End Financial Results Maintain 'No Going Concern' Status